查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1889213

胸廓出口症候群 (TOS) 市场预测至 2032 年：按类型、病因、治疗方法方法、手术入路、血管内治疗、给药途径、最终用户和地区分類的全球分析

Thoracic Outlet Syndrome (TOS) Market Forecasts to 2032 - Global Analysis By Type (Neurogenic TOS, Venous TOS, and Arterial TOS), Cause, Treatment Type, Surgical Approach, Endovascular Intervention, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的一项研究，预计到 2025 年，全球胸廓出口症候群 (TOS) 市场价值将达到 2.8625 亿美元，到 2032 年将达到 23.2723 亿美元，在预测期内的复合年增长率为 34.9%。

胸廓出口症候群（TOS）是指胸廓出口（锁骨和第一肋骨之间的狭窄通道）内的神经和血管受到压迫而引起的一系列疾病。这种压迫会导致肩膀、手臂和手部出现疼痛、麻木和无力等症状。 TOS通常由结构异常、重复性压力、不良姿势或颈部肩部损伤引起。

宣导和教育活动

教育计画和宣传宣传活动正在提高早期症状识别率，从而加快诊断和治疗。医学协会和倡导团体正积极推广有关神经源性、静脉性和动脉性胸廓出口症候群的知识。这种认知的提升鼓励患者寻求专科治疗，进而增加了对先进治疗方法的需求。针对外科医生和临床医生的培训计画正在提高诊断准确性和治疗效果。随着全球教育的扩展，市场正受益于患者参与度的提高和治疗方法接受度的改善。

某些认证核可药短缺

目前的治疗方法通常依赖止痛药、物理治疗和手术干预，而非标靶药物治疗。缺乏特异性治疗药物限制了治疗的个人化和长期管理方案的选择。监管障碍进一步阻碍了胸廓出口症候群（TOS）新型药物疗法的研发。患者和临床医生常常对该领域药物创新的缺乏感到失望。因此，对非药物干预和侵入性手术的依赖限制了市场成长。

微创手术的技术进步

这些手术流程缩短了患者的復原时间，最大限度地减少了併发症，并改善了整体疗效。机器人辅助手术和先进的影像引导等创新技术正在提高手术的精准度。医院和诊所正越来越多地采用这些技术，以满足患者对更安全、更快速治疗的需求。人工智慧驱动的手术规划工具的整合进一步提高了手术效率。随着微创手术的日益普及，它们正在为市场扩张和提高患者满意度开闢新的途径。

报销政策不完善

许多医疗保健系统对外科手术和復健治疗的报销范围有限。病人往往需要承担高昂的自付费用，这常常阻碍他们接受先进的治疗。保险公司在调整报销机制以适应新技术和微创疗法方面进展缓慢。这种经济负担限制了患者获得治疗的机会，尤其是在对医疗成本高度敏感的地区。如果没有相应的报销政策，创新治疗方法的市场推广可能会受到限制。

新冠疫情的影响：

新冠疫情扰乱了择期手术，并延误了胸廓出口症候群（TOS）患者的非紧急就诊。封锁措施和医疗系统不堪负荷导致诊断和治疗被延后。然而，这场危机也加速了远端医疗和远距物理治疗计画的普及。医疗机构已开始优先考虑线上咨询，以维持医疗服务的连续性。疫情后的策略强调在TOS管理中增强韧性、整合数位化资源以及建立灵活的治疗路径。儘管短期需求受到影响，但混合医疗模式的长期应用可望提振市场。

预计在预测期内，神经胸廓出口症候群细分市场将占据最大的市场份额。

由于神经源性胸廓出口症候群（TOS）的盛行率高于静脉型和动脉型TOS，预计在预测期内，神经源性TOS将占据最大的市场份额。神经源性TOS患者常伴随慢性疼痛和功能障碍，因此对治疗的需求不断增加。人们对该疾病的认识不断提高，诊断技术的进步也推动了此症候群的检出率。诊所和医院正加大对神经源性TOS的专项治疗方法投入。研究活动也致力于改善针对该疾病的外科和非外科干预措施。

预计在预测期内，诊所细分市场将呈现最高的复合年增长率。

预计在预测期内，诊所板块将达到最高成长率。病患数量的成长和对便利医疗服务需求的增加正推动诊所拓展服务范围。许多诊所正在采用先进的诊断工具和微创技术来改善治疗效果。提供个人化復健方案的能力也提升了患者的偏好。云端基础的患者管理系统有助于简化工作流程并提高效率。

占比最大的地区：

由于北美拥有先进的医疗基础设施并积极采用创新外科技术，预计在预测期内将占据最大的市场份额。患者和医生较高的健康意识有助于早期诊断和治疗。部分州优惠的报销政策也促进了市场成长。美国和加拿大的主要医院和研究机构正积极致力于研发新的治疗方法。

复合年增长率最高的地区：

由于医疗基础设施的不断完善和外科技术投资的持续增长，预计亚太地区在预测期内将实现最高的复合年增长率。在中国、印度和日本等国家，人们对胸廓出口症候群（TOS）的认知度和诊断率都在不断提高。政府为实现医疗体系现代化所采取的倡议，进一步推动了先进治疗方法。全球和区域公司之间的策略联盟正在促进医疗服务的可及性和技术的转移。

免费客製化服务：

购买此报告的客户可享有以下免费自订选项之一：

  • 公司概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要企业SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，提供主要国家的市场估算和预测，以及复合年增长率（註：可行性需确认）。
  • 竞争基准化分析
    • 根据主要参与者的产品系列、地理覆盖范围和策略联盟基准化分析

目录

第一章执行摘要

第二章 前言

  • 摘要
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球胸廓出口症候群 (TOS) 市场（按类型划分）

  • 神经源性胸廓出口症候群
  • 静脉性胸廓出口症候群
  • 动脉胸廓出口症候群

6. 全球胸廓出口症候群 (TOS) 市场（依病因划分）

  • 神经源性
  • 血管
  • 肌肉骨骼系统

7. 全球胸廓出口症候群 (TOS) 市场（依治疗方法）

  • 保守治疗
  • 手术治疗
  • 药物治疗
  • 物理治疗
  • 其他治疗方法

8. 全球胸廓出口症候群 (TOS) 市场（以手术方式划分）

  • 腋窝入路
  • 锁骨上入路
  • 经胸入路

9. 全球胸廓出口症候群 (TOS) 市场（依血管内治疗划分）

  • 不等边石块
  • 支架置入术
  • 肋骨切除术
  • 血管成形术
  • 溶栓治疗

10. 全球胸廓出口症候群 (TOS) 市场依给药途径划分

  • 口服
  • 肠外

11. 全球胸廓出口症候群 (TOS) 市场（依最终用户划分）

  • 医院
  • 诊所
  • 诊断中心
  • 其他最终用户

12. 全球胸廓出口症候群 (TOS) 市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十三章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十四章 企业概况

  • Pfizer Inc.
  • Amgen Inc.
  • Johnson &Johnson
  • Roche Holding AG
  • Novartis AG
  • Merck &Co., Inc.
  • AbbVie Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Bristol Myers Squibb
  • GlaxoSmithKline plc（GSK）
  • Takeda Pharmaceutical Company Limited
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca plc
Product Code: SMRC32673

According to Stratistics MRC, the Global Thoracic Outlet Syndrome (TOS) Market is accounted for $286.25 million in 2025 and is expected to reach $2327.23 million by 2032 growing at a CAGR of 34.9% during the forecast period. Thoracic Outlet Syndrome (TOS) refers to conditions that occur when nerves or blood vessels are compressed within the thoracic outlet, the narrow passage between the clavicle and first rib. This compression can cause symptoms such as pain, tingling, numbness, or reduced strength in the shoulders, arms, and hands. TOS often develops due to structural variations, repetitive strain, poor posture, or injuries involving the neck or shoulder area.

Market Dynamics:

Driver:

Increased awareness & education

Educational initiatives and awareness campaigns are helping individuals recognize early symptoms, leading to quicker diagnosis and treatment. Medical associations and advocacy groups are increasingly promoting knowledge about neurogenic, venous, and arterial TOS. This rising awareness is also encouraging patients to seek specialized care, boosting demand for advanced therapies. Training programs for surgeons and clinicians are improving diagnostic accuracy and procedural outcomes. As education spreads globally, the market benefits from stronger patient engagement and higher adoption of treatment options.

Restraint:

Lack of specific approved drugs

Current management often relies on pain medications, physiotherapy, and surgical interventions rather than targeted drugs. This lack of dedicated therapeutics restricts treatment personalization and long-term management options. Regulatory hurdles further slow the development of novel drug therapies for TOS. Patients and clinicians often face frustration due to limited pharmaceutical innovation in this area. Consequently, the market growth is restrained by dependence on non-drug interventions and invasive procedures.

Opportunity:

Technological advancements in minimally invasive surgery

The procedures reduce patient recovery time, minimize complications, and improve overall outcomes. Innovations such as robotic-assisted surgery and enhanced imaging guidance are making interventions more precise. Hospitals and clinics are increasingly adopting these technologies to meet patient demand for safer and faster treatments. The integration of AI-driven surgical planning tools is further enhancing procedural efficiency. As minimally invasive approaches gain traction, they open new avenues for market expansion and patient satisfaction.

Threat:

Inadequate reimbursement policies

Many healthcare systems provide limited coverage for surgical procedures and rehabilitation therapies. Patients often face high out-of-pocket expenses, discouraging them from pursuing advanced treatments. Insurance providers are slow to adapt reimbursement frameworks for newer technologies and minimally invasive approaches. This financial burden reduces accessibility, particularly in cost-sensitive regions. Without supportive reimbursement policies, market adoption of innovative therapies may remain restricted.

Covid-19 Impact:

The COVID-19 pandemic disrupted elective surgeries and delayed non-urgent consultations for TOS patients. Lockdowns and strained healthcare systems led to postponed diagnoses and treatments. However, the crisis accelerated the adoption of telemedicine and remote physiotherapy programs. Hospitals began prioritizing digital consultations to maintain continuity of care. Post-pandemic strategies now emphasize resilience, digital integration, and flexible treatment pathways for TOS management. While short-term demand was affected, long-term adoption of hybrid care models is expected to strengthen the market.

The neurogenic TOS segment is expected to be the largest during the forecast period

The neurogenic TOS segment is expected to account for the largest market share during the forecast period, due to its high prevalence compared to venous and arterial forms. Patients with neurogenic TOS often experience chronic pain and functional impairment, driving demand for treatment. Increased awareness and improved diagnostic techniques are leading to higher identification rates. Clinics and hospitals are investing in specialized therapies tailored to neurogenic cases. Research efforts are also focused on refining surgical and non-surgical interventions for this segment.

The clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the clinics segment is predicted to witness the highest growth rate. Rising patient volumes and demand for accessible care are encouraging clinics to expand services. Many clinics are adopting advanced diagnostic tools and minimally invasive techniques to improve outcomes. Their ability to provide personalized rehabilitation programs is also boosting patient preference. Cloud-based patient management systems are helping streamline workflows and enhance efficiency.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the region benefits from advanced healthcare infrastructure and strong adoption of innovative surgical techniques. High awareness levels among patients and physicians contribute to early diagnosis and treatment. Favorable reimbursement frameworks in certain states also support market growth. Leading hospitals and research institutions in the U.S. and Canada are actively engaged in developing new therapies.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, owing to expanding healthcare infrastructure and rising investments in surgical technologies. Countries such as China, India, and Japan are witnessing increased awareness and diagnosis of TOS. Government initiatives to modernize healthcare systems are further supporting adoption of advanced treatments. Strategic collaborations between global and regional players are enhancing accessibility and technology transfer.

Key players in the market

Some of the key players in Thoracic Outlet Syndrome (TOS) Market include Pfizer Inc., Amgen Inc., Johnson & Johnson, Roche Holding AG, Novartis AG, Merck & Co Inc., AbbVie Inc., Eli Lilly and Co, Bayer AG, Bristol Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical, Sanofi S.A., Teva Pharmaceutical, and AstraZeneca.

Key Developments:

In November 2025, Pfizer Inc. announced the successful completion of its acquisition of Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. This strategic milestone represents more than a transaction it's a deliberate investment in the future of medicine.

In November 2025, Amgen announced that the U.S. Food and Drug Administration (FDA) has granted full approval to IMDELLTRA(R) (tarlatamab-dlle) for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

Types Covered:

  • Neurogenic TOS
  • Venous TOS
  • Arterial TOS

Causes Covered:

  • Neurogenic
  • Vascular
  • Musculoskeletal

Treatment Types Covered:

  • Conservative Treatment
  • Surgical Treatment
  • Medication
  • Physical Therapy
  • Other Treatment Types

Surgical Approaches Covered:

  • Transaxillary Approach
  • Supraclavicular Approach
  • Transthoracic Approach

Endovascular Interventions Covered:

  • Scalene Muscle Block
  • Stenting
  • Rib Resection
  • Angioplasty
  • Thrombolysis

Route of Administrations Covered:

  • Oral
  • Parenteral

End Users Covered:

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Thoracic Outlet Syndrome (TOS) Market, By Type

  • 5.1 Introduction
  • 5.2 Neurogenic TOS
  • 5.3 Venous TOS
  • 5.4 Arterial TOS

6 Global Thoracic Outlet Syndrome (TOS) Market, By Cause

  • 6.1 Introduction
  • 6.2 Neurogenic
  • 6.3 Vascular
  • 6.4 Musculoskeletal

7 Global Thoracic Outlet Syndrome (TOS) Market, By Treatment Type

  • 7.1 Introduction
  • 7.2 Conservative Treatment
  • 7.3 Surgical Treatment
  • 7.4 Medication
  • 7.5 Physical Therapy
  • 7.6 Other Treatment Types

8 Global Thoracic Outlet Syndrome (TOS) Market, By Surgical Approach

  • 8.1 Introduction
  • 8.2 Transaxillary Approach
  • 8.3 Supraclavicular Approach
  • 8.4 Transthoracic Approach

9 Global Thoracic Outlet Syndrome (TOS) Market, By Endovascular Intervention

  • 9.1 Introduction
  • 9.2 Scalene Muscle Block
  • 9.3 Stenting
  • 9.4 Rib Resection
  • 9.5 Angioplasty
  • 9.6 Thrombolysis

10 Global Thoracic Outlet Syndrome (TOS) Market, By Route of Administration

  • 10.1 Introduction
  • 10.2 Oral
  • 10.3 Parenteral

11 Global Thoracic Outlet Syndrome (TOS) Market, By End User

  • 11.1 Introduction
  • 11.2 Hospitals
  • 11.3 Clinics
  • 11.4 Diagnostic Centers
  • 11.5 Other End Users

12 Global Thoracic Outlet Syndrome (TOS) Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Pfizer Inc.
  • 14.2 Amgen Inc.
  • 14.3 Johnson & Johnson
  • 14.4 Roche Holding AG
  • 14.5 Novartis AG
  • 14.6 Merck & Co., Inc.
  • 14.7 AbbVie Inc.
  • 14.8 Eli Lilly and Company
  • 14.9 Bayer AG
  • 14.10 Bristol Myers Squibb
  • 14.11 GlaxoSmithKline plc (GSK)
  • 14.12 Takeda Pharmaceutical Company Limited
  • 14.13 Sanofi S.A.
  • 14.14 Teva Pharmaceutical Industries Ltd.
  • 14.15 AstraZeneca plc

List of Tables

  • Table 1 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Neurogenic TOS (2024-2032) ($MN)
  • Table 4 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Venous TOS (2024-2032) ($MN)
  • Table 5 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Arterial TOS (2024-2032) ($MN)
  • Table 6 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Cause (2024-2032) ($MN)
  • Table 7 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Neurogenic (2024-2032) ($MN)
  • Table 8 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Vascular (2024-2032) ($MN)
  • Table 9 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Musculoskeletal (2024-2032) ($MN)
  • Table 10 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 11 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Conservative Treatment (2024-2032) ($MN)
  • Table 12 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Surgical Treatment (2024-2032) ($MN)
  • Table 13 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Medication (2024-2032) ($MN)
  • Table 14 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Physical Therapy (2024-2032) ($MN)
  • Table 15 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 16 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Surgical Approach (2024-2032) ($MN)
  • Table 17 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Transaxillary Approach (2024-2032) ($MN)
  • Table 18 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Supraclavicular Approach (2024-2032) ($MN)
  • Table 19 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Transthoracic Approach (2024-2032) ($MN)
  • Table 20 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Endovascular Intervention (2024-2032) ($MN)
  • Table 21 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Scalene Muscle Block (2024-2032) ($MN)
  • Table 22 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Stenting (2024-2032) ($MN)
  • Table 23 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Rib Resection (2024-2032) ($MN)
  • Table 24 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Angioplasty (2024-2032) ($MN)
  • Table 25 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Thrombolysis (2024-2032) ($MN)
  • Table 26 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 27 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Oral (2024-2032) ($MN)
  • Table 28 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 29 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By End User (2024-2032) ($MN)
  • Table 30 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 31 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 32 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 33 Global Thoracic Outlet Syndrome (TOS) Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.